DFTX Latest Headlines

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX), Tenax Therapeutics (TENX) and MoonLake Immunotherapeutics (MLTX)

at www.tipranks.com (Mon, 10-Aug 1:00 PM)

Evercore ISI Sticks to Its Buy Rating for Definium Therapeutics (DFTX)

at www.tipranks.com (Mon, 10-Aug 8:45 AM)

Definium Therapeutics: Buy Rating Reiterated on Strong Clinical and Financial Positioning; $74 Price Target Maintained

at www.tipranks.com (Fri, 7-Aug 6:55 PM)

Definium Therapeutics (DFTX) Gets a Buy from Jefferies

at www.tipranks.com (Fri, 7-Aug 3:16 PM)

Definium Therapeutics (DFTX) Receives a Buy from Oppenheimer

at www.tipranks.com (Fri, 7-Aug 8:55 AM)

Analysts Conflicted on These Healthcare Names: Amphastar Pharmaceuticals (AMPH), Tenax Therapeutics (TENX) and Definium Therapeutics (DFTX)

at www.tipranks.com (Fri, 7-Aug 8:20 AM)

Piper Sandler Remains a Buy on Definium Therapeutics (DFTX)

at www.tipranks.com (Fri, 7-Aug 8:09 AM)

Analysts Conflicted on These Healthcare Names: Astrana Health (ASTH), Resmed (RMD) and Definium Therapeutics (DFTX)

at www.tipranks.com (Fri, 7-Aug 6:30 AM)

Ami Fadia Reiterates Buy on Definium Therapeutics, Keeps $50 Price Target Ahead of Key GAD Phase 3 Readouts

at www.tipranks.com (Thu, 6-Aug 9:35 PM)

Definium Therapeutics Posts Strong Phase 3 Data and Capital Raise to Fund Psychedelic Pipeline

at www.tipranks.com (Thu, 6-Aug 7:33 PM)

Mind Medicine GAAP EPS of -$1.44 misses by $0.91

at seekingalpha.com (Thu, 6-Aug 4:03 PM)

Definium Therapeutics Sets August 6 Date to Report Q2 2026 Results

at www.tipranks.com (Thu, 6-Aug 1:00 PM)

Definium Therapeutics Launches ‘Wired for Worry’, Addressing Critical Gaps in GAD Awareness and Clinical Tools

Market Chameleon (Thu, 16-Jul 7:06 AM)

Definium's $700 Million Upsized Offering Draws Spotlight on Biotech Expansion

Market Chameleon (Wed, 24-Jun 10:33 AM)

Definium Therapeutics’ $700 Million Upsized Public Offering Highlights Strategic Push on Next-Gen Neuropsychiatric Therapies

Market Chameleon (Wed, 24-Jun 7:49 AM)

Definium Therapeutics Launches $500 Million Public Offering: Funding Psychedelic Innovation for Mental Health

Market Chameleon (Tue, 23-Jun 11:07 AM)

DFTX Draws Attention With Upcoming Phase 3 Results Webcast on Major Depressive Disorder

Market Chameleon (Mon, 22-Jun 10:31 AM)

DT120 Phase 3 Data Shows Rapid and Durable Improvement in Depression – Single Dose Achieves 8.1-Point MADRS Advantage at 6 Weeks

Market Chameleon (Mon, 22-Jun 7:07 AM)